Recalled products — current list 2026
Recalls in Poland are issued by GIS (Chief Sanitary Inspector) for food and cosmetics, GIF (Chief Pharmaceutical Inspector) for medicines, and UOKiK for consumer products. The list below brings every alert together in one place and is updated continuously as new recalls are published.
2 162 alerts in the database • last update:
Latest recalled products
Febrisan
A quality defect was found consisting of micro-damages in the structure of the primary packaging foil, which may lead to loss of tightness and deterioration of the medicine’s quality. Potencjalne skutki: reduced treatment efficacy or adverse reactions.
Silimax
Irregularities in batch number labelling were found: containers with batch number 05022020 were packed into cartons incorrectly marked as 02022020, preventing unambiguous identification of the product batch. Potential effects: risk of mix-ups and hindered recall in case of safety issues.
Bufomix Easyhaler
A quality defect was identified in the Easyhaler inhaler, in the reservoir chamber containing the inhalation powder; as a defect of the immediate packaging it may affect the medicinal product quality and dose delivery. Potential effects: lack of treatment efficacy, possible worsening of disease symptoms.
Formoterol Easyhaler
A quality defect of the Easyhaler inhaler was found in the reservoir chamber containing the inhalation powder; the impact of this defect on the quality and correct dosing of the medicinal products cannot be excluded, creating a potential risk to patients’ health or life. Potential effects: lack of efficacy, disease exacerbation, respiratory complications.
Nitroxolin forte
An impurity 5,7-Dinitro-8-quinolinol (DNC) was identified in the active substance and classified as a mutagenic impurity, whose content should be lower than currently approved limits. Potential effects: increased risk of DNA damage, cancer and other complications.
Hemkortin-HC
Incorrect strength of the medicinal product was found on the immediate (tube) packaging, which may mislead patients or medical staff about the dose being used. Potential effects: improper dosing, lack of therapeutic efficacy or increased adverse reactions.
VERSO stroller (carrycot + pushchair)
During a 200 N force test, the safety harness buckle released unintentionally, which may cause the child to fall out of the stroller. Additionally, the required age warning label is missing. Potential effects: child falling from stroller, injuries.
Biodacyna
A quality defect was found: an out‑of‑specification result for the colour parameter in a parenterally administered medicinal product, which entails a potential risk to patients’ health or life. Potential effects: complications after intravenous or intramuscular administration, lack of treatment safety.
Tlen medyczny Air Products
An unusual odour was detected in one of the cylinders from the batch of the medicinal product Medical oxygen Air Products, indicating a quality defect of the medical gas and a potential health risk to patients when used. Potential effects: irritation of the respiratory tract, unspecified adverse reactions, lack of safety of oxygen therapy.
Zerbaxa
Microbiological contamination was detected in batches of Zerbaxa, indicating a quality defect that may pose a real risk to patients’ health or life. Potential effects: infection, sepsis, treatment complications, lack of therapeutic efficacy.
Tramal
A quality defect was found consisting of unglued outer packaging of the product, which may affect the safety and correct use of the medicine. Potential effects: possible compromise of packaging integrity, risk of improper use or dosing errors.
ride-on board with seat Mr Buggy MS Moby - System
Test results showed that during use the nuts fastening the seat to the platform unscrew, causing seat instability and risk of the child falling out. The buckle adjusters can detach and as small parts create a choking hazard. Potential effects: child fall, injuries, choking.
Triderm
The occurrence of incorrect information on the outer packaging regarding the repackaging site and the name of the parallel importer was classified as a quality defect of the medicinal product. Potential effects: incorrect use of the drug, inability to identify the responsible entity, possible therapy complications.
Lisinoratio 5
Suspected contamination of the batch of Lisinoratio 5, 5 mg, tablets with ibuprofen as an undesired substance, which is a potential quality defect that may endanger patients’ health. Potential effects: adverse reactions, drug interactions, complications involving kidneys and cardiovascular system.
Oxydolor
Stability studies of the product batches showed an out-of-specification result for active substance content, which may lead to incorrect dosing of the medicine. Potential effects: lack of treatment efficacy or overdose, complications, risk to health.
Krople uspokajające spokojne
the tested sample of the medicinal product Krople uspokajające spokojne did not meet the requirements specified in the product documentation for total aerobic microbial count (TAMC). This quality defect may pose a potential risk to the health or life of patients. Potential effects: infections, complications, health risk.
Gliceryna
It was found that test results for batches of the pharmaceutical raw material GLICERYNA 85% are out of specification for the parameters: aldehydes and sugars, which means failure to meet established quality requirements for a medicinal product. Potential effects: reduced quality of preparations, possible irritation or other adverse reactions.
Timo-COMOD 0,5 %
Irregularities in the assembly of the dispenser pump housing were found, resulting in improper drop size or inability to dispense drops from the dispenser. Potential effects: lack of treatment efficacy, incorrect dosing, possible worsening of the eye condition.
Allergo-Comod
Irregularities in the assembly of the dispenser pump housing were found, causing incorrect drop size or inability to dispense drops from the bottle. Potential effects: lack of treatment efficacy, worsening of allergy symptoms, possible discomfort or eye irritation.
Octostim
Incorrect volume was detected in some packs and out-of-specification results for the content of the active substance desmopressin and the excipient benzalkonium chloride. Potential effects: lack of treatment efficacy or adverse effects due to incorrect dosing.
Minirin
In some packs, an incorrect liquid volume and results not complying with the specification for desmopressin and benzalkonium chloride content were found, meaning the dose and safety of the product cannot be assured. Potential effects: lack of treatment efficacy or overdose, adverse reactions, complications.
Dicortineff
Occurrence of a quality defect in the medicinal product in the fludrocortisone acetate parameter, confirmed in stability testing and an archival sample. Potential effects: possible lack of treatment efficacy or unpredictable adverse reactions.
Ventolin
The quality defect consists in marking the batch with a unique identifier indicating in the system that the batch is withdrawn, which prevents dispensing the product to patients and may lead to lack of availability of the medicine. Potential effects: lack of effective treatment, deterioration of health.
Megalia
Out-of-specification results were found regarding microbiological purity in batches of the medicinal product Megalia. Potential effects: infection, complications, risk to patients' health.
Uromaste
Use of the product, for which the benefit–risk balance was assessed as negative, poses a threat to public health; there is a significant probability of real harm to patients’ health or life. Potential effects: treatment complications, lack of efficacy, threat to health or life.
Monural
Use of this product, for which the benefit–risk ratio has been considered negative, poses a threat to public health. Potential effects: serious adverse reactions, health risk, possible complications.
Nasen
A quality defect consisting in placing in the outer packaging of one medicinal product the blisters of another medicinal product, creating a risk that the patient will take the wrong medicine. Potential effects: inappropriate treatment, lack of therapeutic efficacy, serious adverse reactions.
Furosemidum Polfarmex
The quality defect involves a mix-up of Furosemidum Polfarmex and Nasen packs, creating a risk that patients take the wrong medicine and consequently face a threat to their life or health. Potential effects: lack of efficacy, increased adverse effects, serious complications, life-threatening situations.
Sulfarinol
An out-of-specification result was obtained in stability testing for batch 020618 concerning the parameter “naphazoline nitrate contamination – other single impurity”, with the possibility that this quality defect may occur in other batches still on the market. Potential effects: nasal mucosa irritation, adverse reactions or reduced treatment effectiveness.
Groprinosin Max
Out-of-specification results were found in antimicrobial preservation efficacy tests for Groprinosin MAX, meaning lack of adequate preservation and a risk of infection after use. Potential effects: infections, complications, health risk for patients.
Cisatracurium Noridem
The tested sample of the medicinal product does not meet the requirements specified in the documentation for active substance content and product appearance, which creates a potential risk to patients' health or life. Potential effects: lack of treatment efficacy, complications during anaesthesia, life-threatening risk.
Megalia
Failure to meet quality requirements for the batch regarding microbiological purity, which poses a potential risk to patients’ health or life and was the basis for granting the decision immediate enforceability. Potential effects: infection, complications, lack of treatment safety.
Montelukast Bluefish
A discrepancy was found between the outer packaging and the Summary of Product Characteristics – a product intended for children aged 6–14 years was labelled as for children 2–5 years, which poses a threat to public health. Potential effects: improper use in children, risk of lack of efficacy or adverse effects.
Ebetrexat
It was found that the sample did not meet the product specification requirements for purity; the out-of-specification result concerned the parameter "content of related substance impurities". Potential effects: altered drug effect, possible increased adverse reactions or complications of therapy.
Megalia
Failure to meet quality requirements for this batch was found regarding the microbiological purity parameter, which may indicate the presence of microorganisms in the product and a potential risk to patients' health. Potential effects: infections, adverse reactions, lack of treatment efficacy.
Saridon
It was found that the packaging materials do not meet requirements – some packs of the product are labeled in Hungarian, which may lead to misunderstanding of information about the medicine. Potential effects: incorrect use of the medicine, lack of efficacy, complications.
Reseligo
A result out of specification was found for active substance content, indicating a quality defect that may lead to improper drug action. Potential effects: treatment failure or adverse reactions.
Sulfarinol
Out-of-specification results were found in tested archival samples for the listed Sulfarinol batches regarding the parameter naphazoline nitrate impurity – another single impurity. Potential effects: possible adverse reactions, lack of efficacy or other complications related to uncontrolled impurity.
Sulfarinol
Out-of-specification results were found in archival samples for the parameter naphazoline nitrate contamination – another single impurity, which creates a potential risk to patients’ health or life. Potential effects: mucosal irritation, systemic adverse effects, lack of therapeutic efficacy.
Tetmodis
Out-of-specification results were found for active substance content in batch T1702PL of Tetmodis (Tetrabenazine), which may mean an inappropriate dose for the patient. Potential effects: lack of efficacy or increased adverse effects.
Sulfarinol
Out-of-specification results were found in archival samples of Sulfarinol batches for the parameter “naphazoline nitrate contamination – other single impurity”, indicating a quality defect of the product. Potential effects: reduced treatment efficacy and possible adverse reactions of unpredictable intensity.
Mitomycin Accord
A quality defect was found consisting in the inability to dissolve the powder, which may prevent preparation of a correct injection/infusion solution and result in failure to administer the proper drug dose. Potential effects: lack of treatment efficacy, complications of oncological therapy.
Sulfarinol
The tested retention samples showed out-of-specification results for the parameter “naphazoline nitrate contamination – other single impurity”, which may indicate the presence of an undesirable chemical compound in the product. Potential effects: possible adverse effects, irritation, lack of efficacy or other unpredictable reactions.
Espumisan 100 mg/ml
In several packs of the product, information leaflets for the medicinal product Zentel were detected instead of the correct Espumisan leaflet. Potential effects: incorrect use of the medicine, risk of improper dosing or lack of treatment efficacy.
Riflux
Contamination of the active substance Ranitidine with N-nitrosodimethylamine (NDMA) was detected, constituting a quality defect and a potential risk to patients’ health. Potential effects: possible toxic and carcinogenic effects during long-term use.
Debridat
A potential quality defect was reported due to the risk of a foreign body being present in the product, which may pose a real and direct risk to patients’ health or life. Potential effects: complications, tissue damage, life-threatening events.
Debridat
Risk of a quality defect in the medicinal product Debridat, 7.87 mg/g, granules for oral suspension, due to the risk of the presence of a foreign body in the product. Potential effects: gastrointestinal injuries, complications, possible threat to the patient’s health or life.
Debridat
Risk of presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension. Potential effects: mechanical damage, complications, irritation of the gastrointestinal tract.
Debridat
Risk of the presence of a foreign body in the medicinal product, possibly due to a potential quality defect. Potential effects: mechanical damage to the gastrointestinal tract, complications, need for medical intervention.
Debridat
Risk of a potential quality defect consisting in the presence of a foreign body in the product. Potential effects: mechanical injuries, gastrointestinal complications, risk to health or life.
Debridat
Risk of the presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension, which may cause gastrointestinal damage or other mechanical complications during use. Potential effects: mechanical injuries, complications, risk to health or life.
Apra-swift
A printing inconsistency in the dose on one side of the outer packaging was found (15 mg stated incorrectly, it should be 30 mg). Potential effects: improper dosing, lack of treatment efficacy or adverse effects.
Debridat
Risk of presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension, which may expose the patient to mechanical damage of the gastrointestinal tract or other complications during use. Potential effects: injuries, complications, health risk.
Raniberl Max
Contamination of the active substance ranitidine with N-nitrosodimethylamine (NDMA) was detected, causing the batches to be deemed non-compliant with quality requirements and potentially hazardous to patients’ health or life. Potential effects: carcinogenic action, organ damage, general poisoning.
Lakcid forte
The test showed that the product sample does not comply with the specification regarding the CFU count of lactic acid bacteria (Lactobacillus rhamnosus), which may mean a lower content of live probiotic bacteria than declared. Potential effects: lack of treatment efficacy, possible worsening of symptoms, delay of therapy.
Lakcid forte
It was found that the product sample does not comply with the specification regarding the number of lactic acid bacteria CFU, which may lead to reduced therapeutic effectiveness of the probiotic preparation. Potential effects: reduced treatment effectiveness, lack of the expected probiotic effect.
Flavamed
A possible increased level of impurity E was identified in batches manufactured using glass bottles from one of the suppliers, which constitutes a quality defect of the medicinal product. Potential effects: possible adverse reactions or reduced treatment safety.
NuTRIflex Omega plus
Cases of product discoloration were found, possibly accompanied by phase separation of the emulsion, indicating a quality defect of a solution intended for intravenous infusion. Potential effects: lack of therapeutic efficacy, metabolic disturbances, complications during parenteral nutrition.
NuTRIflex Omega special
Cases of product discoloration were found, possibly accompanied by phase separation of the emulsion, indicating potential instability of the intravenously administered preparation. Potential effects: lack of treatment efficacy, infusion-related complications, adverse reactions.
Flavamed
Tests by the National Medicines Institute confirmed that the sample of Flavamed batch 82014 did not meet purity specification requirements due to an exceeded level of impurity E, which makes a potential health risk for patients plausible. Potential effects: possible adverse reactions, complications, reduced treatment safety.
Browse recalls by topic
Frequently asked questions
What are GIS alerts?
GIS (Chief Sanitary Inspector) alerts are official warnings about food products that have been recalled from the Polish market due to health hazards like salmonella, listeria, E. coli or foreign objects.
What are GIF alerts?
GIF (Chief Pharmaceutical Inspector) alerts are warnings about pharmaceutical products and medicines that have been recalled due to quality or safety issues.
What are UOKiK alerts?
UOKiK (Office of Competition and Consumer Protection) alerts are warnings about dangerous consumer products in Poland, including toys, electronics and household items that pose safety risks.
What to do if you bought a recalled product?
Stop using or consuming the product immediately. Most recalled products can be returned to the store for a full refund, even without a receipt. On each alert page you will find a direct link to the official GIS/GIF report with detailed information from the authorities.
What to do if you have this product?
A recall means the product may be unsafe. Here is what to do if you have it at home.
-
1
Do not eat or use the product
Stop using or consuming it immediately and keep it out of reach of children.
-
2
Check the batch number and expiry date
Compare the batch/lot number and the best-before or expiry date with the details in the alert — sometimes only specific batches are affected.
-
3
Return it to the shop
You can take the product back to the shop where you bought it. For a safety recall a refund is due even without a receipt.
-
4
Get help and report it
If you feel unwell after using the product, contact a doctor. You can also report the case to the relevant authority — GIS, GIF or UOKiK.
General guidance for recalled products in Poland. Always follow the specific instructions in the official alert and from the manufacturer or retailer.